Reconstitution of the CD56+ lymphocyte subsets in BM versus PBPC recipients, and patients in group 1 versus group 2
| . | BMT (n = 14) . | PBPC (n = 4) . | Group 1 (n = 8) . | Group 2 (n = 5) . |
|---|---|---|---|---|
| CD56+, K/μL | ||||
| Day 30 | 0.22 ± 0.03 | 0.26 ± 0.04 | 0.26 ± 0.04 | 0.18 ± 0.04 |
| Day 60 | 0.17 ± 0.03 | 0.16 ± 0.06 | 0.17 ± 0.04 | 0.17 ± 0.05 |
| Day 90/100 | 0.17 ± 0.03 | 0.19 ± 0.06 | 0.18 ± 0.06 | 0.17 ± 0.04 |
| Day 180 | 0.17 ± 0.04 | 0.17 ± 0.04 | 0.11 ± 0.02 | 0.24 ± 0.07 |
| Day 365 | 0.14 ± 0.03 | 0.07 ± 0.03 | 0.11 ± 0.04 | 0.13 ± 0.05 |
| CD56dim, % of CD56+ | ||||
| Day 30 | 51.9 ± 6.7 | 66.6 ± 7.2 | 55.5 ± 10.2 | 62.7 ± 7.8 |
| Day 60 | 54.3 ± 5.4 | 72.3 ± 7.6 | 59.1 ± 7.8 | 57.1 ± 11.5 |
| Day 90/100 | 55.6 ± 6.6 | 67.2 ± 5.0 | 53.3 ± 10.0 | 51.9 ± 10.2 |
| Day 180 | 76.4 ± 5.5 | 79.2 ± 12.5 | 81.5 ± 2.4 | 61.8 ± 13.8 |
| Day 365 | 79.3 ± 4.7 | 84.5 ± 6.3 | 86.1 ± 2.1* | 58.1 ± 6.2* |
| . | BMT (n = 14) . | PBPC (n = 4) . | Group 1 (n = 8) . | Group 2 (n = 5) . |
|---|---|---|---|---|
| CD56+, K/μL | ||||
| Day 30 | 0.22 ± 0.03 | 0.26 ± 0.04 | 0.26 ± 0.04 | 0.18 ± 0.04 |
| Day 60 | 0.17 ± 0.03 | 0.16 ± 0.06 | 0.17 ± 0.04 | 0.17 ± 0.05 |
| Day 90/100 | 0.17 ± 0.03 | 0.19 ± 0.06 | 0.18 ± 0.06 | 0.17 ± 0.04 |
| Day 180 | 0.17 ± 0.04 | 0.17 ± 0.04 | 0.11 ± 0.02 | 0.24 ± 0.07 |
| Day 365 | 0.14 ± 0.03 | 0.07 ± 0.03 | 0.11 ± 0.04 | 0.13 ± 0.05 |
| CD56dim, % of CD56+ | ||||
| Day 30 | 51.9 ± 6.7 | 66.6 ± 7.2 | 55.5 ± 10.2 | 62.7 ± 7.8 |
| Day 60 | 54.3 ± 5.4 | 72.3 ± 7.6 | 59.1 ± 7.8 | 57.1 ± 11.5 |
| Day 90/100 | 55.6 ± 6.6 | 67.2 ± 5.0 | 53.3 ± 10.0 | 51.9 ± 10.2 |
| Day 180 | 76.4 ± 5.5 | 79.2 ± 12.5 | 81.5 ± 2.4 | 61.8 ± 13.8 |
| Day 365 | 79.3 ± 4.7 | 84.5 ± 6.3 | 86.1 ± 2.1* | 58.1 ± 6.2* |
Means are shown ± SEM. Differences between patient groups tested by Student t-test.
Significant difference (P < .05).